The compounds synthesized in this study were evaluated for their ability to inhibit in vitro ADP-induced platelet aggregation of guinea pig platelet rich plasma (PRP) ( Tables  1-3) .
Platelets play an important role in the pathogenesis of thrombotic diseases such as acute myocardial infarction, unstable angina and cerebral thrombosis. [1] [2] [3] [4] The binding of the plasma protein fibrinogen to platelet glycoprotein IIb/IIIa (GPIIb/IIIa) via the Arg-Gly-Asp (RGD) recognition sequence, is the final obligatory step in the platelet aggregation cascade stimulated by various mediators such as adenosine 5Ј-diphosphate (ADP) and collagen. 5, 6) Therefore, GPIIb/IIIa antagonists are expected to inhibit platelet aggregation more extensively than the various inhibitors of the individual mediators. [7] [8] [9] [10] In the last decade, intensive effort has been devoted to the development of GPIIb/IIIa inhibitors as an attractive new type of antithrombotic agent. [11] [12] [13] [14] [15] [16] [17] [18] The clinical efficacy of GPIIb/IIIa antagonists, including some monoclonal antibodies, cyclic peptides and low molecular weight non-peptides, has been validated. For example, use of the anti-GPIIb/IIIa c7E3 Fab antibody (ReoPro) in high-risk patients undergoing percutaneous transluminal coronary angioplasty (PTCA), has been shown to reduce the composite incidence of major ischemic events, including the need for revascularization. 19, 20) Previous studies on the structure-activity relationships (SAR) of GPIIb/IIIa antagonists demonstrated that appropriately spaced guanidino and carboxylate equivalents were a critical prerequisite for inhibitory activity, and that a Gly residue was an essential part for high affinity for GPIIb/IIIa in a series of RGD-containing peptides and peptide mimetics. 13) However, Alig et al. demonstrated that the Gly residue could be replaced with other amino acids or linkers without loss of activity. 21) Recently, we reported the design and synthesis of the potent and orally active GPIIb/IIIa antagonist 1 (TAK-029), 22) which was designed from tetrapeptides such as RGDS, RGDF and RGDV using conformational constraint by incorporation of cyclic structures (Chart 1). Since the effect of the Gly moiety of 1 was not previously examined, we have performed detailed modification of this part in an effort to find compounds with greater activity and better pharmacological profiles than 1. In this paper, we describe the design, synthesis and biological activities of 2-oxopiperazine derivatives containing various amino acids in place of the Gly residue of 1. We also discuss the SAR of our new compounds, which imply the existence of an additional binding site in GPIIb/IIIa besides the known ionic interaction sites. Although there are some reports on modification of the Gly residue of RGD-containing peptides and peptide mimetics, there have been few reports on detailed SAR focused on the substituent at the Gly position.
Chemistry
The general synthetic route for the target compounds 4a-w is outlined in Chart 2. Condensation of 2 22) with various Nprotected a-amino acids using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) in methylene dichloride provided the intermediates 3a-w. Conversion of 3a-w to 4a-w was achieved by one of two routes depending on the nitrogen-protecting group utilized. In the case where the protective group was a benzyloxycarbonyl (Z) group, hydrogenolysis of 3a-l in the presence of 10% Pd-C followed by acylation with 4-amidinobenzoylchloride hydrochloride and subsequent acid hydrolysis of the tert-butyl ester group afforded 4a-l (method A). When a tert-butoxycarbonyl (Boc) group was used, simultaneous acid hydrolysis of the Boc group and tert-butyl ester group of 3m-w followed by acylation with 4-amidinobenzoylchloride hydrochloride gave 4m-w (method B).
Conversion of the vinyl intermediate 3v to the 4-ethyl derivative 10, formyl derivative 11, hydroxymethyl derivative To improve the in vitro and in vivo potency of our first low molecular weight GPIIb/IIIa antagonist 1 (TAK-029), a series of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic acids were synthesized through modification of the glycine moiety of 1 and evaluated for their ability to inhibit in vitro adenosine 5-diphosphate (ADP)-induced platelet aggregation of guinea pig platelet rich plasma (PRP). Among the compounds examined, the (3S,2S)-4-methoxyphenylalanine derivative 4h showed the most potent antagonistic activity with an IC 50 value of 13 nM. Dose-dependent inhibition of ex vivo platelet aggregation was achieved with oral administration of 4h (0.3-1.0 mg/kg) to guinea pigs. Complete inhibition was observed for up to 8 h, and 43% inhibition could still be observed 24 h after oral administration of 1.0 mg/kg. The long-lasting antiplatelet effect of 4h suggests that 4h would be suitable for once-a-day dosing. Structure-activity relationships (SAR) were examined in the series of the phenylalanine derivatives. An increase in the electron density around the 4-position of the phenyl ring of the phenylalanine moiety led to an increase in the antiplatelet activity, suggesting the existence of a hydrophobic and electrostatic interaction site in addition to the ionic binding sites in the GPIIb/IIIa. 12 and carboxyl derivative 13 is depicted in Chart 3. Hydrogenation or oxidative cleavage of the double bond of 3v gave the 4-ethyl or 4-formyl intermediate (6, 7) , respectively. Reduction of 7 with NaBH 4 , or oxidation of 7 with KMnO 4 , afforded the 4-hydroxymethyl or 4-carboxyl intermediate (8, 9) , respectively. These intermediates 6-9 were converted to the corresponding target compounds 10-13 using method B described in Chart 2.
Novel Non-Peptide GPIIb/IIIa Antagonists: Synthesis and Biological Activities of 2-[4-[2-(4-Amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acids
Amino derivatives were synthesized as shown in Chart 4. Hydrogenation of 3w afforded the aniline 14. Reductive methylation of 14 using excess 37% aqueous HCHO and NaBH 3 CN, afforded the dimethylamino intermediate 15. The sequential benzylation, methylation and de-benzylation of 14 gave the methylamino intermediate 16. These amino intermediates 14-16 were also converted to the corresponding target compounds 17-19 using method B.
Compounds 5a-c (Table 2) , stereoisomers of 4a, were prepared in a manner similar to that described for 4a using Z-
The phenylalanine derivatives used in the preparation of 4 were synthesized as follows (Chart 5). Simultaneous alkylation and esterification of 20a-c followed by hydrolysis of the ester groups gave 21a-h. 23) Treatment of 23, which was obtained from Z-L-Tyr-O t Bu (22) with trifluoromethanesulfonic anhydride (Tf 2 O) and 2,6-lutidine, with CO gas in the presence of palladium (II) acetate (Pd(OAc) 2 ) 24) in MeOH followed by acid hydrolysis, provided the 4-methoxycarbonylphenylalanine 25. Treatment of 27 with ethynyltributyltin or vinyltributyltin 25) in the presence of dichlorobis-(triphenylphosphine)palladium(II) (PdCl 2 (PPh 3 ) 2 ) and LiCl followed by hydrolysis, gave the corresponding 4-ethynyland 4-vinylphenylalanine (30, 31), respectively. mer 5c. The chiral centers in the phenylalanine derivatives are considered to play a significant role in GPIIb/IIIa recognition. Table 3 shows the influence of the substituents on the phenyl group in the (3S,2S )-phenylalanine derivatives. Among the compounds examined, the 4-methoxyphenylalanine derivative 4h showed the most potent inhibitory activity (IC 50 : 13 nM), and the other compounds inhibited platelet aggregation with IC 50 values of 22 to 11000 nM.
Interesting SAR were observed in these phenylalanine derivatives. At the beginning, we thought that the remarkably enhanced potency of 4a, as compared to that of 4c, could be ascribed to hydrogen bond formation between the phenolic hydroxyl group (hydrogen bond donor) and the GPIIb/IIIa (hydrogen bond acceptor), or coordination of the hydroxyl group with the Ca 2ϩ ions existing around GPIIb. 27) However, hydrogen bonding was found not to be an important factor, since the 4-methoxy derivative 4h, which lost the nature of the phenolic hydroxyl group, showed potent inhibitory activity. Moreover, coordination of the hydroxyl group with the Ca 2ϩ ions was also found not to be the reason, because the 3,4-dihydroxyphenyl derivative 4m, which was expected to have enhanced coordination with the Ca 2ϩ ions, showed slightly less potent activity than 4a.
We then changed our focus to the hydrophobic and electrostatic interaction between the ligand and the GPIIb/IIIa, since the fluoro derivative 4s showed greater activity than 4c. We assumed that an electron negative cloud around the 4-position of the phenyl ring of the phenylalanine moiety, caused by such things as a lone pair of electrons of the oxygen atom or enhancement of the electron density resulting from the high electronegativity of the fluoro atom on the phenyl ring, interacts with an electron positive site on the receptor. This hypothesis is supported by the results as follows. Conversion of the methylene or methyl group in ethyl derivative 10 into an oxygen atom (the methoxy derivative 4h and hydroxymethyl derivative 12) resulted in a 41-or 17-fold increase in inhibitory activity, respectively. Enhancement of the electron density by introduction of an unsaturated bond, led to an increase in potency (4o, 4p vs. 4j; 4u, 4v vs. 10). The presence of a methoxycarbonyl group or formyl group at the 4-position of the phenyl ring increased the potency (4t, 11 vs. 4c).
On the other hand, lowering the electron density of the oxygen atom by introducing a fluoro atom at the 3-or 2-position of the phenyl ring resulted in a decrease in the potency (4q, 4r vs. 4a). The amino derivatives 17, 18 and 19, and the carboxyl derivative 13, showed remarkably decreased activity. The high hydrophilicity of these ionic functional groups might negatively interact with the hydrophobic site on the receptor. The size of the functional group was also an important factor; an increase in the bulkiness of the functional group decreased the potency. Lengthening or branching of the alkyl chain led to a decrease in potency (4h-n).
From these results, we propose the existence of a binding site, other than the site of ionic interaction in the GPIIb/IIIa, which is dependent on hydrophobic and electrostatic interaction (Fig. 1) . The possible existence of a hydrophobic binding site in the GPIIb/IIIa has been previously suggested by a couple of research groups 15, 28) ; however, the hydrophobic binding site we discovered in the present study is characterized by its electrostatic feature.
A comparison of the pharmacological profiles of 4h with 1 is shown in Table 4 and Figs. 2 and 3. Derivative 4h inhibited the binding of biotin-labeled human fibrinogen to immobilized human GPIIb/IIIa and in vitro ADP-induced aggregation of human and monkey platelets more potently than 1 ( Table 4) . Dose-dependent inhibition of ex vivo platelet ag- gregation induced by ADP was achieved with oral administration of 0.3-1.0 mg/kg of 4h to guinea pigs, and complete inhibition was observed for up to 8 h, and 43% inhibition could still be observed 24 h after oral administration of 1.0 mg/kg (Fig. 2 ). Intravenous administration of 4h (0.003-0.01 mg/kg) to guinea pigs also inhibited platelet aggregation dose dependently (Fig. 3 ). Oral and intravenous administration of 4h showed approximately 10-fold greater antiplatelet activity than 1. In our previous pharmacokinetics study of 1 in rats, the dicarboxyl derivative was not observed in plasma after oral administration of 1. The ester group at the 3-position of the 2-oxopiperazine scaffold was assumed to be stable in plasma, and the ester form (1) was regarded as the biological active form by itself (unpublished data). Therefore, in the case of 4h, we considered that the ester form (4h) is the biological active form by itself as well as 1.
Conclusion
Modification of the Gly moiety of 1 has led to the potent, orally active and long-acting GPIIb/IIIa antagonist 4h, which showed approximately 3-and 10-fold more potent in vitro and ex vivo antiplatelet effects, respectively, than 1. Derivative 4h exhibited increased potency as compared to 1 in the human and monkey platelet aggregation assays as well as in the guinea pig assay. The SAR obtained in this study revealed the existence of a hydrophobic and electrostatic interaction site, in addition to the ionic binding sites in the GPIIb/IIIa. A hydrophobic electron negative cloud around the 4-position of the phenyl ring of the phenylalanine moiety may enhance the interaction between the fibrinogen receptor and the antagonists.
Experimental
Melting points were determined on a Yanagimoto micro melting point apparatus and are uncorrected. IR spectra were obtained on a Hitachi IR-215 spectrometer. Compounds 3a-g and 3i-w were prepared in a manner similar to that described for 3h. Compounds 3b-g, 3m, 3q-3r and 3u were used for a next reaction without purification. 41 mmol) and 10% Pd-C (0.14 g) in MeOH (4.2 ml) was stirred at room temperature for 40 min. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo to give a colorless syrup, which was dissolved in H 2 O (11.7 ml) and 1,4-dioxane (5.9 ml). To this solution were added NaHCO 3 (0.24 g, 2.81 mmol) and 4-amidinobenzoylchloride hydrochloride (0.37 g, 1.69 mmol) at room temperature. After being stirred for 1.5 h, the mixture was adjusted to pH 7 with 1 N HCl and concentrated in vacuo. Then, a mixture of the residue and toluene (5.9 ml) was treated with trifluoroacetic acid (5.9 ml) and the mixture was stirred for 1 h at room temperature. 
General Synthetic Procedure (Method B). 2-[(3S)-4-[(2S)-2-(4-Amidinobenzoylamino)-3-(4-nitrophenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid (4w)
To a solution of 3w (1.60 g, 2.77 mmol) in toluene (8.0 ml) was added trifluoroacetic acid (8.0 ml) at room temperature. After being stirred for 1 h, the mixture was concentrated in vacuo, and the resulting oil was dissolved in H 2 O (30 ml) and 1,4-dioxane (15 ml). To the solution were added NaHCO 3 (0.93 g, 11.1 mmol) and 4-amidinobenzoylchloride hydrochloride (0.79 g, 3.60 mmol) at room temperature, and the mixture was stirred for 30 min. Then, the mixture was adjusted to pH 2 with 1 N HCl and concentrated in vacuo. The residue was purified by means of CHP-20 column chromatography (gradient elution: H 2 O to 25% aqueous MeCN) to give 4w (1.12 g, 68%) as a colorless crystalline powder Compounds 4a-g, 4i-v and 5a-c were prepared in a manner similar to that described for 4h (method A) or 4x (method B).
2-[(3S )-4-[(2S )-2-(4-Amidinobenzoylamino)-3-(4-hydroxyphenyl)-propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid (4a):
Method A (46% from 3a) 
-[(3S )-4-[(2S )-2-(4-Amidinobenzoylamino)phenylethanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid (4d): Method

-[(3S )-4-[(2S )-2-(4-Amidinobenzoylamino)-4-carboxybutanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid (4f): Z-L-Glu
Methyl 2-[(2S )-1-[(2S )-2-[(tert-Butoxycarbonyl)amino]-3-(4-formylphenyl)propanoyl]-4-[2-(tert-butoxy)-2-oxoethyl]-3-oxopiperazinyl]acetate (7)
To a mixture of 3v (2.21 g, 3.95 mmol), NaIO 4 (3.46 g, 16.2 mmol), CCl 4 (22.1 ml), MeCN (22.1 ml) and H 2 O (33.2 ml) was added RuCl 3 · nH 2 O (16.4 mg, 0.079mmol) at room temperature. After being stirred for 1 h at room temperature, the mixture was extracted with EtOAc. The EtOAc extract was dried over anhydrous MgSO 4 and concentrated in vacuo.
The 
2-[(3S )-4-[(2S )-2-(4-Amidinobenzoylamino)-3-(4-formylphenyl)-propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid (11)
Compound 11 was prepared from 7 using method
4-[(2S )-2-[(tert-Butoxycarbonyl)amino]-3-[(2S )-4-[2-(tert-butoxy)-2-oxoethyl]-2-(2-methoxy-2-oxoethyl)-3-oxopiperazinyl]-3-oxopropyl]benzoic Acid (9)
To a mixture of 7 (0.48 g, 0.86 mmol), acetic acid (AcOH) (0.24 ml) and acetone (4.8 ml) was added KMnO 4 (0.14 g, 0.86 mmol) at 0°C. After being stirred for 40 min at 0°C and for 1 h at room temperature, the mixture was poured into H 2 O and extracted with EtOAc. The EtOAc extract was dried over anhydrous MgSO 4 , AcOH (0.1 ml, 1.72 mmol) and MeCN (11.0 ml) was added NaBH 3 CN (0.17 g, 2.75 mmol) at room temperature. After being stirred for 2 h, the mixture was purified by the procedure described above to give the Nbenzyl-N-methylamino intermediate (1.10 g, 98%) as a colorless syrup. Then, a suspension of this intermediate and 10% Pd-C (0.44 g) in MeOH (11.0 ml) was stirred for 2 h at room temperature under an H 2 atmosphere. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo. The residue was chromatographed on SiO 2 (hexane-EtOAc, 1:2) to give 16 (0.95 g, 100%) as a colorless syrup. IR (KBr) cm 2-[(tert-Butoxycarbonyl)amino]-3-[4-[(trifluoromethylsulfonyl) (
4-[(2S )-2-(4-Amidinobenzoylamino)-3-[(2S )-4-(carboxymethyl)-2-(2-methoxy-2-oxoethyl)-3-oxopiperazinyl]-3-oxopropyl]benzoic
2-[(3S )-4-[(2S )-2-(4-Amidinobenzoylamino)-3-(4-aminophenyl)-propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic
Ethyl (2S )-
2S )-2-[(tert-Butoxycarbonyl)amino]-3-(4-ethynylphenylphenyl)-propanoic Acid (30)
Compound 30 was prepared in a manner similar to that described for 31 and used for a next reaction without purification.
Fibrinogen Binding Studies Human platelet GPIIb/IIIa was purified from a human erythroleukemia cell line and used for the binding assay. In brief, 100 ml of GPIIb/IIIa complex (1.0 mg/ml) in a buffer containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl 2 and 0.02% NaN 3 (pH 7.4) was added to 96-well microtiter plates and incubated for 48 h at 4°C. After blocking non-specific binding sites with a blocking agent (Block Ace, Dainippon Pharmaceutical Co., Osaka, Japan) for 3 h at room temperature, biotinatedfibrinogen (1 mg/ml) with various concentrations of test compounds was added to the receptor-coated wells and incubated for 18 h at room temperature. Bound biotinated-fibrinogen was measured by an ELISA using anti-biotin rabbit antibody-conjugated alkaline phosphatase and p-nitrophenyl phosphate as the substrate.
Platelet Aggregation Studies In Vitro: Blood was collected by venipuncture from healthy human volunteers and Cynomolgus monkeys. Guinea pigs were anesthetized with sodium pentobarbital and blood was collected by aortic puncture. Blood was withdrawn into a plastic syringe containing 3.8% (human and monkey) or 3.15% (guinea pig) sodium citrate (1 : 10 citrate/blood, v/v). PRP and platelet-poor plasma (PPP) were obtained by centrifugation at 1000ϫg for 3-5 s and 1000ϫg for 20 min at room temperature, respectively. The platelet count in PRP was adjusted to 3ϫ10 5 /ml (human, monkey) and 4ϫ10 5 /ml (guinea pig) using an automatic blood cell counter (Sysmex E2500, Toaiyoudenshi Co., Tokyo, Japan). Platelet aggregation was measured using an 8 channel aggregometer (Hematracer VI, Niko Bioscience, Tokyo, Japan). PRP (250 ml), in a cuvette stirred at 1000 rpm, was prewarmed for 2 min at 37°C with various concentrations of test compounds (25 ml). The change in light transmittance was measured after the addition of aggregating agents (25 ml) to the cuvette. Submaximal concentrations of aggregating agents were used in each experiment.
Ex Vivo: Male Hartley guinea pigs (300-400 g) were used. At various times after i.v. or p.o. administration of test compounds, blood was collected, and PRP and PPP were prepared as described for the in vitro study. ADP (20 ml) was added to the cuvette containing the prewarmed PRP (220 ml). In order to eliminate the possible influence of the sensitivity differences of guinea pig platelets to ADP, which is dependent on the animal lot and experimental conditions including drug administration protocol, two or three vehicle-treated animals were used as a control at each measuring point. The percentage inhibition of platelet aggregation in drug-treated animals was determined by comparison with the aggregation in the controls at each point.
